Shares of Shaily Engineering Plastics are likely to remain in focus on Wednesday, May 20, after the company announced regulatory approvals and launch of a customer combination product incorporating its ShailyPen Neo device technology.
According to the company’s press release, the combination product has secured USFDA tentative approval, Health Canada notice of compliance and regulatory approval from India’s CDSCO for generic semaglutide injection incorporating the ShailyPen Neo spring driven variable and fixed dose pen injector platform.
The company said its strategic partner Orbicular Pharmaceutical Technologies, along with its customer, has launched a generic version of semaglutide injection in Canada using Shaily’s proprietary ShailyPen Neo platform. The product has already been commercially available in India since March 2026.
ShailyPen Neo is described by the company as a spring driven pen injector platform compatible with ISO standard 3 mL cartridges, supporting both variable and fixed dose formats. Shaily said its role in the program includes design, development, manufacturing and supply of device components used in the approved combination product.
Managing Director Amit Sanghvi said the development reflects the company’s long term investment in spring actuated pen injector technology and large scale industrial manufacturing capabilities.
The company operates in healthcare, consumer and engineering plastics segments, with its healthcare business focused on drug delivery systems including pen injectors, autoinjectors and specialty delivery devices.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.